hVIVO plc (LON:HVO - Get Free Report) traded down 48.6% during trading on Friday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.32 ($0.11). 74,283,875 shares changed hands during mid-day trading, an increase of 2,124% from the average session volume of 3,339,384 shares. The stock had previously closed at GBX 16.20 ($0.22).
Analyst Ratings Changes
Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research note on Friday.
View Our Latest Analysis on hVIVO
hVIVO Price Performance
The stock has a market capitalization of £61.56 million, a P/E ratio of 3.59 and a beta of 0.97. The stock's fifty day moving average is GBX 16.16 and its 200-day moving average is GBX 18.13. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.
hVIVO (LON:HVO - Get Free Report) last issued its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, equities analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.
Insiders Place Their Bets
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($700,459.93). Company insiders own 14.03% of the company's stock.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Stories
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
